Brought to you by 
Nuvo issues $Cdn13mm in stock to buy Zars Pharma
16 May 2011
Executive Summary
Canadian drug company Nuvo Research Inc. has acquired privately held Zars Pharma Inc. (topical drug administration). Nuvo will issue 101.5mm shares (approximately 19.5% of its outstanding stock), worth $Cdn13.1mm ($13.2mm) based on the ten-day pre-announcement average.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nuvo issues $Cdn13mm in stock to buy Zars Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice